Bridging the gap between discovery and clinical implementation in #cancer #immunotherapy #immunooncology at @HerlevGentofte Copenhagen. SoMe manager @doniamarco
Capital Region, Denmark
Joined April 2018
- Tweets253
- Following62
- Followers443
- Likes513
CCIT-DK: National Center for Cancer Immune Therapy retweeted
❓What are the outcomes of checkpoint inhibitors after progression to TIL therapy in #melanoma?
👇Check the work led by the brilliant James Smithy of @MSKCancerCenter with multiple international groups including our team at @CCITdk
New #JITC short report: "Immune checkpoint inhibitor therapy after tumor-infiltrating lymphocytes in unresectable melanoma" jitc.bmj.com/content/14/6/e0…
@DrBetofMDPhD @ShirlyGrynberg @ajsfurness @ja_ocejo @bbuchbinderMD @LutzkyJose
@evanlipson @DoniaMarco @HaanenJohn
CCIT-DK: National Center for Cancer Immune Therapy retweeted
🔵 Just published in @JNCI_Now: pCR and ctDNA clearance prognostic dynamics after neoadjuvant/perioperative IO
Pan-tumor reconstructed IPD analysis | 1,867 pCR + 352 ctDNA-clearance patients | 8 tumor types
-3-yr EFS after pCR ranges from 78.6% (#NSCLC) to 100% (dMMR-#CRC)
-No EFS benefit from postoperative adjuvant IO in patients achieving pCR (cross-trial)
-#ctDNA clearance shows heterogeneous prognostic value
📢A call towards an individualized neo/periop treatment
🔗academic.oup.com/jnci/advanc…
🧙♂️👉 @DoniaMarco, @ProfCUBlankNKI, @MARIANOPROVENCI & @ChristianRolfo
#Immunotherapy
CCIT-DK: National Center for Cancer Immune Therapy retweeted
🔵 Our new paper in @JNCI_Now: do reimbursed drugs deliver in routine care what trials promised?
A new framework quantifies the efficacy-effectiveness gap from a national registry (🇩🇰,DAMMED).
In #melanoma:
- IO deviated only in ineligible pts (HR 1.61)
- Targeted therapy deviated even in eligible ones
🔍The method is exportable to any registry-backed disease.
🧙♂️ Senior and corresponding 👉@DoniaMarco
📚Full paper 👇👇👇
CCIT-DK: National Center for Cancer Immune Therapy retweeted
How well do #melanoma trial results predict routine-care outcomes?
👉In first-line metastatic melanoma it turns on two things: trial eligibility and drug class.
New @JNCI_Now paper. 🇩🇰Danish registry, 1909 patients, vs reconstructed
trial data. 🧵
doi.org/10.1093/jnci/djag196
CCIT-DK: National Center for Cancer Immune Therapy retweeted
All complete responses to immunotherapy are created equal: across tumour types, not across response depth.
Two papers from @CCITdk , two methods, one conclusion. 🧵
CCIT-DK: National Center for Cancer Immune Therapy retweeted
📣 Our new paper in @JNCCN: acquired resistance to #immunotherapy (ARI) across 11 tumor types
Reconstructed IPD: 15,199 pts / 41 phase 3 trials
• 73.5% develop ARI by 3y
• Higher CR/PR → less ARI, regardless of tumor type
ARI may be determined by response depth, not histology
Cheers to @DoniaMarco & @CCITdk 🇩🇰
Full paper 👇👇👇
CCIT-DK: National Center for Cancer Immune Therapy retweeted
📣 New in #EJC: among PD-(L)1 responders, durability tracks response depth, not tumor type
Our nationwide cohort 🇩🇰: 2,127 responders (#melanoma, #RCC, #NSCLC)
• Within CR & within PR, PFS near-identical across tumors
• PR vs CR = dominant factor
Two papers, two faces of the same coin 🪙:
response depth, not tumor type, drives the risk of acquired resistance to IO
Trial-level (@JNCCN) + real-world (#EJC), same conclusion
Cheers to @DoniaMarco & @CCITdk
Full paper 👇👇
#LCSM #IO
CCIT-DK: National Center for Cancer Immune Therapy retweeted
🎥 @holmstrom_mo of @CCITdk shares outcomes from a study investigating immune reconstitution in patients with #Myelofibrosis conditioned with a non-myeloablative regimen prior to alloSCT:
➡️ ow.ly/9zC550YXw7F
#MPNsm #BMTsm #HemOnc #ESHMPN2026
CCIT-DK: National Center for Cancer Immune Therapy retweeted
In a recent interview, @holmstrom_mo of @CCITdk discussed the potential of therapeutic cancer vaccines in MPNs, highlighting the challenges of integrating vaccine strategies into treatment. 💉🩸
Click here to watch the full interview:
🎥 👉 ow.ly/cBWP50YXv1I
#ESHMPN2026 #MPNsm #ImmunoOnc #HemOnc
CCIT-DK: National Center for Cancer Immune Therapy retweeted
🆕 Nationwide real-world (DAMMED 🇩🇰) study comparing Dab/Tram vs Enco/Bini in 751 pts with BRAFm metastatic melanoma.
⚖️ No differences in efficacy
🧩 Consistent across subgroups
(incl. 🧠 mets)
📄 doi.org/10.1093/jnci/djaf263
In @JNCI_Now
@CCITdk @DoniaMarco #Melanoma #Oncology
CCIT-DK: National Center for Cancer Immune Therapy retweeted
Acquired resistance to Cancer Immunotherapy
Free at bit.ly/4jptfZz
➡️ Metastatic cancers can be cured
➡️ Pts who initially respond can develop resistance (up to 65% of responders)
❗One of the top priorities in Oncology
Reviewed in @TrendsMolecMed
@CCITdk @MdCurioni
CCIT-DK: National Center for Cancer Immune Therapy retweeted
New #JITC article: Arginase-1-specific T cells target and modulate tumor-associated macrophages bit.ly/3PZKkMP @marper2323 @CCITdk
CCIT-DK: National Center for Cancer Immune Therapy retweeted
📢 Check out this special case report by Monberg, Svane & colleagues @CCITdk @helsinkiuni @Rigshospitalet 🇩🇰🇫🇮.
💉Combined treatment with TILs + oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma.
Available #OpenAccess 👇esmoiotech.org/article/S2590…
CCIT-DK: National Center for Cancer Immune Therapy retweeted
New publication on #MPNsm from @CCITdk published in @BrJHaem: Peripheral blood lymphocytes (PBL) from patients with CALR mutant #MPNsm display increased levels of surface TGFb and GARP. Probably mediated by enhanced binding of activated platelets to PBL.
doi.org/10.1111/bjh.19711
CCIT-DK: National Center for Cancer Immune Therapy retweeted
💬 Fantastic keynote lecture by Dr. Inge Marie Svane from @CCITdk on TIL therapies at VHIO under the framework of #PragamTIL Annual Meeting.
CCIT-DK: National Center for Cancer Immune Therapy retweeted
Despite manufacturing costs ~67 000 €, academic TIL therapy for patients with #melanoma is both cost-saving and cost-effective in 🇩🇰 and 🇱🇺
Publicly-funded #celltherapy can be sustainable!
New #JITC article: Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial bit.ly/3PG0IlP @DoniaMarco @tenHamR @HaanenJohn @ValescaRetel
CCIT-DK: National Center for Cancer Immune Therapy retweeted
Excited to share our latest article on @jitcancer, where we show that a TGFβ-based immune modulatory vaccine can both directly and indirectly modulate the phenotype of TAMs and CAFs, two high TGFβ-secreting cell subsets in the TME ➡ lnkd.in/dpyf9MPJ @CCITdk
CCIT-DK: National Center for Cancer Immune Therapy retweeted
New #JITC review: Biomarkers for response to TIL therapy: a comprehensive review bit.ly/43g4Yhe @Vic_albarran @pballestin @DoniaMarco
CCIT-DK: National Center for Cancer Immune Therapy retweeted
Harnessing neoantigen-specific T cells for precision cancer immunotherapy
👉 @NatRevClinOncol, Jan 2024, free access link at rdcu.be/dwp89
💬 about "Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers" @YosephRami
CCIT-DK: National Center for Cancer Immune Therapy retweeted
Published today! Dissecting tumor microenvironment heterogeneity in syngeneic mouse models: insights on cancer-associated fibroblast phenotypes shaped by infiltrating T cells frontiersin.org/articles/10.… @CCITdk @FrontImmunol